Compare ARVN & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARVN | GPRK |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 706.1M |
| IPO Year | 2018 | 2009 |
| Metric | ARVN | GPRK |
|---|---|---|
| Price | $6.79 | $9.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $14.00 | $11.23 |
| AVG Volume (30 Days) | ★ 859.5K | 752.1K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 1.14% |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | $5.67 | $17.63 |
| Revenue Next Year | N/A | $16.73 |
| P/E Ratio | ★ $7.78 | $12.70 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.33 | $6.84 |
| 52 Week High | $14.22 | $13.13 |
| Indicator | ARVN | GPRK |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 33.18 |
| Support Level | $6.74 | $8.98 |
| Resistance Level | $7.85 | $10.06 |
| Average True Range (ATR) | 0.47 | 0.40 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 27.06 | 18.78 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.